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Abstract
Background: To better understand the need for paediatric second-line antiretroviral therapy (ART), an ART
management survey and a cross-sectional analysis of second-line ART use were conducted in the TREAT Asia
Paediatric HIV Observational Database and the IeDEA Southern Africa (International Epidemiologic Databases to
Evaluate AIDS) regional cohorts.
Methods: Surveys were conducted in April 2009. Analysis data from the Asia cohort were collected in March 2009
from 12 centres in Cambodia, India, Indonesia, Malaysia, and Thailand. Data from the IeDEA Southern Africa cohort
were finalized in February 2008 from 10 centres in Malawi, Mozambique, South Africa and Zimbabwe.
Results: Survey responses reflected inter-regional variations in drug access and national guidelines. A total of 1301
children in the TREAT Asia and 4561 children in the IeDEA Southern Africa cohorts met inclusion criteria for the
cross-sectional analysis.
Ten percent of Asian and 3.3% of African children were on second-line ART at the time of data transfer. Median
age (interquartile range) in months at second-line initiation was 120 (78-145) months in the Asian cohort and 66
(29-112) months in the southern African cohort. Regimens varied, and the then current World Health Organization-
recommended nucleoside reverse transcriptase combination of abacavir and didanosine was used in less than 5%
of children in each region.
Conclusions: In order to provide life-long ART for children, better use of current first-line regimens and broader
access to heat-stable, paediatric second-line and salvage formulations are needed. There will be limited benefit to
earlier diagnosis of treatment failure unless providers and patients have access to appropriate drugs for children to
switch to.
Background
An estimated 2.5 million children worldwide are living
with HIV [1], and more than 354,000 of them were on
antiretroviral treatment (ART) at the end of 2009. Glo-
bal paediatric treatment coverage is estimated at 28%
after applying revised World Health Organization
(WHO) ART initiation criteria [1,2]. Once children are
on treatment, the cumulative risk of treatment failure
continues to increase over time. Social support, nutri-
tional supplements, counselling, medication records,
home-based care and transportation reimbursements are
only a few of the many resources that are used to pro-
mote adherence to delay this outcome.
Despite being in early stages of the paediatric ART
scale up, children are already failing treatment and
needing second-line regimens. Current United Nations
estimates of paediatric second-line use in low- and mid-
dle-income countries (LMICs; outside of the Americas)
are around 3% [1]. However, this is much lower than in
* Correspondence: annette.sohn@treatasia.org
1TREAT Asia/amfAR - The Foundation for AIDS Research, Bangkok, Thailand
Full list of author information is available at the end of the article
TApHOD and IeDEA Journal of the International AIDS Society 2011, 14:7
http://www.jiasociety.org/content/14/1/7
© 2011 TREAT Asia Paediatric HIV Observational Database (TApHOD) and The International Epidemiologic Databases to Evaluate AIDS
(IeDEA) Southern Africa Paediatric Group; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the
Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
reproduction in any medium, provided the original work is properly cited.single cohort reports in settings where ART has been
available for longer periods of time. A survey of 17 cen-
tres in LMICs in Asia reported that 20% of the more
than 3600 children under care were already past their
first ART regimens [3]. Other single-institution cohorts
have reported as much as 5.8% (South Africa [4]), 9%
(Thailand [5]), and 19.4% (south India [6]) of patients
switching to second-line regimens.
Evidence-based strategies for selecting second-line
regimens are needed, but are also dependent on local
antiretroviral (ARV) options. Children have consistently
faced greater disadvantages with regards to the availabil-
ity of ARV formulations that can be dosed and delivered
to children, and that are safe to use during growth and
development [7,8].
To better understand the growing need for paediatric
second-line ART, we conducted a survey of two regional
cohorts - in Asia and southern Africa - to determine
second-line use and ARV access, and compare nationally
recommended regimens to explore how regimen
sequencing is being approached in these regions.
Methods
Survey
A survey regarding second-line ART use was conducted
in the TREAT Asia Pediatric HIV Observational Data-
base (TApHOD) and the International Epidemiologic
Databases to Evaluate AIDS (IeDEA) Southern Africa
regional cohorts in April 2009. TApHOD was estab-
lished in 2008 and includes 16 clinical centres in six
countries, 12 of which currently submit patient-level
data to the cohort study (Table 1). The programme is
coordinated by TREAT Asia/amfAR (Bangkok, Thai-
land) with data management support from the National
Centre in HIV Epidemiology and Clinical Research
(NCHECR; Sydney, Australia). IeDEA Southern Africa
was formed in 2007, and includes 10 clinical sites that
provide ART for children in four countries, all of which
submit data to their cohort study. It is a research colla-
boration coordinated by the University of Cape Town
(South Africa) and the University of Bern (Switzerland).
Site-level questions queried access to nucleoside/
nucleotide reverse transcriptase inhibitors (NRTI/
NtRTIs) and protease inhibitors (PIs) commonly used in
internationally recommended ART regimens. Drug
access was designated as “easy” (i.e., regular and consis-
tent access and supply), “somewhat difficult” (i.e., occa-
sional difficulties in accessing and/or obtaining),
“difficult” (i.e., frequent difficulties in accessing and/or
obtaining), or “cannot or do not access” (i.e., drug was
not available or clinicians did not use). Nationally
recommended paediatric ART regimens were obtained
from individual country guidelines, when available, or by
self-report from site principal investigators.
Observational cohort data
In each regional cohort study, participating sites submit
anonymized, patient-level data to their regional data
management centres for data cleaning and analysis.
TApHOD data are submitted twice a year. Data
included in this survey were collected in March 2009
from 12 centres in Cambodia, India, Indonesia, Malaysia
and Thailand. Data from the IeDEA Southern Africa
cohort were finalized in February 2008 from 10 centres
in Malawi, Mozambique, South Africa and Zimbabwe.
Cross-sectional data on first- and second-line ART use
in children who were alive, on ART, and actively under
care as of the data submission date were eligible for
inclusion. Children in the cohort who had previously
been documented to have died, been transferred out of
the site, or were lost to follow up were consequently
excluded from the analysis.
In order to more accurately reflect clinical outcomes
with current paediatric ART management practices
using highly active three-drug regimens and to avoid
potential misclassification of second-line regimens, chil-
dren also were excluded in the following circumstances:
1) first ART regimens were unknown or missing from
the database; 2) first ART regimens were either mono-
or dual-therapy; or 3) first ART regimens contained
didanosine. Children using didanosine were excluded in
order for the analysis cohort to more closely reflect
standard, WHO-recommended first-line regimens [9].
Second-line switches were defined as a change in two
or more ARVs, including a class switch, i.e., from non-
nucleoside reverse transcriptase inhibitors (NNRTIs) to
PIs or visa versa, or if a single-drug class switch was
made on the basis of reported treatment failure; regi-
mens could not be reverted for at least 24 weeks to
avoid including changes due to temporary stock outs.
Descriptive statistics were conducted in SAS and
STATA.
Results
All sites in TREAT Asia (n = 16) and IeDEA Southern
Africa (n = 10) responded to the survey (Table 1).
Nationally recommended first-line ART regimens were
consistent with WHO guidelines, and were most com-
monly combinations of stavudine or zidovudine with
lamivudine and nevirapine or efavirenz. The four Malay-
sian hospitals allowed for the use of didanosine in the
first-line NRTI backbone. In addition, boosted PIs were
recommended in some centres when previous NNRTI
exposure was known (Cambodia, China, Mozambique).
South Africa recommended a boosted PI for first-line
treatment of all children under three years of age or
weighing less than 10 kilograms.
All recommended second-line regimens for children
failing NNRTI-based first-line ART included ritonavir-
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Site Country Nationally recommended
paediatric first-line ART
regimen*
Nationally recommended
paediatric second-line ART
regimen after NNRTI
Most commonly used
second-line regimen in
current site cohort
TREAT Asia
National Center for HIV, AIDS,
Dermatology, and Sexually
Transmitted Infections
Cambodia d4T or AZT+3TC+NVP or EFV
If NNRTI exposure:
d4T+3TC+LPV/r
ABC+ ddI+LPV/r ABC+3TC+LPV/r
Beijing Ditan Hospital China d4T or AZT+3TC+NVP or EFV
If NNRTI exposure:
AZT+3TC+LPV/r
ABC+3TC+AZT+LPV/r ABC+3TC+AZT+LPV/r
YRG Centre for AIDS Research
and Education
India d4T or AZT+3TC+NVP or EFV <3 yr:
ABC+ddI+3TC+LPV/r
>3 yr:
TDF+3TC or FTC+LPV/r
TDF or ddI+3TC or FTC+LPV/
r
Cipto Mangunkusumo Hospital Indonesia d4T or AZT+3TC+NVP or EFV ddI+3TC+LPV/r ddI+3TC+LPV/r
Hospital Kuala Lumpur Malaysia <3 yr:
AZT+3TC or ddI+NVP
≥3 yr:
AZT+3TC or ddI+EFV
2 new NRTI+LPV/r d4T+3TC+LPV/r
Hospital Likas Malaysia <3 yr:
AZT+3TC or ddI+NVP
≥3 yr:
AZT+3TC or ddI+EFV
2 new NRTI+LPV/r d4T+ddI+LPV/r
Hospital Penang Malaysia <3 yr:
AZT+3TC or ddI+NVP
≥3 yr:
AZT+3TC or ddI+EFV
2 new NRTI+LPV/r –
Hospital Raja Perempuan Zainab Malaysia <3 yr:
AZT+3TC or ddI+NVP
≥3 yr:
AZT+3TC or ddI+EFV
2 new NRTI+LPV/r d4T+ddI+LPV/r
Chiang Mai University Medical
Centre
Thailand d4T or AZT+3TC+NVP or EFV ddI+ABC or 3TC+PI/r AZT+3TC+LPV/r
Chiang Rai Regional Hospital Thailand d4T or AZT+3TC+NVP or EFV ddI+ABC or 3TC+PI/r AZT+3TC+LPV/r
HIV-NAT Thailand d4T or AZT+3TC+NVP or EFV ddI+ABC or 3TC+PI/r AZT+3TC+LPV/r
Khon Kaen University Medical
Centre
Thailand d4T or AZT+3TC+NVP or EFV ddI+ABC or 3TC+PI/r AZT+ddI+LPV/r
Siriraj Hospital Thailand d4T or AZT+3TC+NVP or EFV ddI+ABC or 3TC+PI/r AZT+ddI+LPV/r
Children’s Hospital 1 Vietnam d4T+3TC+NVP ABC+ddI+LPV/r –
Children’s Hospital 2 Vietnam d4T+3TC+NVP ABC+ddI+LPV/r ABC+ddI+LPV/r
National Hospital of Pediatrics Vietnam d4T+3TC+NVP ABC+ddI+LPV/r ABC+ddI+LPV/r
IeDEA Southern Africa
Lighthouse Clinic Malawi d4T+3TC+NVP ABC+ddI+LPV/r AZT+3TC+LPV/r
Paediatric Day Hospital, Maputo Mozambique d4T or AZT+3TC+NVP or EFV
If NNRTI exposure:
d4T or AZT+3TC+LPV/r
ABC+ddI+LPV/r None
Rahima Moosa Mother and Child
Hospital
South Africa <3 yr/10 kg:
d4T+3TC+LPV/r
>3 yr/10 kg:
d4T+3TC+EFV
AZT+ddI+LPV/r ABC+3TC+LPV/r
Gugulethu Community Health
Centre
South Africa <3 yr/10 kg:
d4T+3TC+LPV/r
>3yr/10kg:
d4T+3TC+EFV
AZT+ddI+LPV/r AZT+ddI+EFV or LPV/r
ABC+3TC+LPV/r
Harriet Shezi Clinic South Africa <3 yr/10 kg:
d4T+3TC+LPV/r
>3 yr/10 kg:
d4T+3TC+EFV
AZT+ddI+LPV/r AZT+ddI+LPV/r
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the WHO-recommended combination of abacavir and
didanosine to substituting with another thymidine
analogue (i.e., zidovudine for stavudine). A third of the
sites continued lamivudine in second-line regimens.
Malaysian and South African sites, representing 42% of
all sites, had specific national recommendations for sec-
ond-line regimens after initial PI failure that advised use
of two new NRTIs and either nevirapine or efavirenz
(data not shown).
There was some variability in levels of drug access
between the regions (Table 2). IeDEA Southern Africa
had better access to abacavir and ritonavir suspension;
TREAT Asia sites had better access to tenofovir and
paediatric, heat-stable boosted lopinavir tablets.
Although all of the African sites had access to the adult
version of the boosted lopinavir, 80% found it either dif-
ficult to access the liquid or paediatric formulation of
the tablet, or did not use it for their patients. This was
related to delays at the time of the survey in the drug’s
approval by the South African Medicines Control Coun-
cil that have since been resolved.
A total of 1301 children in the TREAT Asia and 4561
children in the IeDEA Southern African cohorts met
inclusion criteria for the cross-sectional analysis (Tables 3
and 4). Although stavudine was infrequently used in Asia,
it was part of the first-line regimen in 92% of children in
southern Africa. Ten percent of Asian and 3.3% of African
children were on second-line ART at the time of data
transfer. Asian children were on second-line ART for
longer periods and were older at the time of switch. Afri-
can children on second-line ART were more frequently
male (67%). Regimens varied widely, and the WHO-
recommended combination at the time of the data transfer
of abacavir and didanosine [10] was used in less than 5%
of children in each region.
Discussion
The percentage of children on second-line in the IeDEA
Southern Africa cohort was similar to United Nations
estimates, but it was three times higher in the TREAT
Asia cohort. Although southern African data were col-
lected one year earlier, this marked difference may be
related to the longer history of paediatric ART in Asia
relative to the more recent scale up observed in south-
ern Africa.
In fact, we are likely to have underestimated the use of
second-line ART in the Asian cohort, since 18% of chil-
dren excluded from this analysis had a previous expo-
sure to mono- and dual-NRTI regimens. In addition,
these differences may be related to regional variation in
the availability of clear second-line switch criteria, and
broader access to viral load testing in Asia.
H o w e v e r ,t h e s ed a t ar e f l e ct only those currently on
second-line treatment. Estimates for how many children
are ready to switch to second-line ART now and projec-
tions for the future are critically needed in order to pre-
pare providers, governments and donors. If the need for
second-line ART is based on virologic failure alone, the
numbers in need would be much higher.
In Asia, 15% of children in a Cambodian study and 37%
of children in a Chinese study had viral loads of more
than 1000 copies/ml after 12 months of first-line ART
[11,12]. An earlier Thai cohort reported that 17% of
Table 1 First- and second-line antiretroviral therapy regimens in use in TREAT Asia and IeDEA Southern Africa
(Continued)
Khayelitsha Community Health
Centre
South Africa < 3 yr/10 kg:
d4T+3TC+LPV/r
>3 yr/10 kg:
d4T+3TC+EFV
AZT+ddI+LPV/r AZT+ddI+LPV/r
McCord Hospital South Africa <3 yr/10 kg:
d4T+3TC+LPV/r
>3 yr/10 kg:
d4T+3TC+EFV
AZT+ddI+LPV/r AZT+ddI+LPV/r
Red Cross Children’s Hospital South Africa <3 yr/10 kg:
d4T+3TC+LPV/r
>3 yr/10 kg:
d4T+3TC+EFV
AZT+ddI+LPV/r AZT+ddI+EFV
Tygerberg Hospital South Africa <3 yr/10 kg:
d4T+3TC+LPV/r
>3 yr/10 kg:
d4T+3TC+EFV
AZT+ddI+LPV/r AZT+ddI+LPV/r
Newlands Clinic Zimbabwe AZT+3TC+NVP ddI+3TC+LPV/r d4T+3TC+NVP
*Content reflects current recommendations at the time of the survey. WHO first-line regimen recommendations at the time of the survey included two NRTIs
with one NNRTI or two NRTIs with one PI/r if the infant had previous NNRTI exposure [10,17]; second-line regimen recommendations after NNRTI failure included
two NRTIs with one PI/r or unboosted nelfinavir in limited circumstances.
d4T - stavudine; AZT - zidovudine; 3TC - lamivudine; NVP - nevirapine; EFV - efavirenz; ABC - abacavir; ddI - didanosine; LPV/r - ritonavir-boosted lopinavir; TDF -
tenofovir; FTC - emtricitabine; NRTI - nucleoside reverse transcriptase inhibitor; NNRTI - non-nucleoside reverse transcriptase inhibitor.
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Similarly, a study done in southern Africa using the cut-
off of more than 1000 copies/ml reported a cumulative
probability of failure by three years after ART initiation
of 19.3% [13], and a study of children and adolescents in
Uganda reported 26% with viral loads of more than 400
copies/ml after 12 months of treatment [14].
Even in settings where viral load is routinely available,
paediatricians are less inclined to switch children who
have persistent viremia unless adherence to a new regi-
men can be assured and the benefits of a new regimen
outweigh the risks of running out of ART options.
Furthermore, when the initial regimen includes a
boosted PI, low-level viremia may not indicate resistance
to the PI. Most importantly, the decision to switch ART
at a young age in countries that only have two lines of
national ART regimens can leave children with no sup-
pressive regimens by adolescence. That the median age
at switch in IeDEA Southern Africa was 5.5 years was
especially concerning because of the lack of available
third-line options that these young children now have.
This may reflect the impact of NNRTI resistance after
prevention of mother to child transmission interven-
tions, which can also be a factor in ART management
after first-line PI failure in those infants who are started
on boosted lopinavir.
Another notable finding was that only 33% of the chil-
dren on second-line treatment in the southern African
cohort were female. However in an analysis using the
same data of factors that predict switch to second-line
Table 2 Levels of access to commonly used second-line antiretroviral drugs in TREAT Asia and IeDEA Southern Africa
Categories of drug access
Antiretroviral* Easy to access Somewhat difficult to access Difficult to access Cannot or do not access
TA SA TA SA TA SA TA SA
ABC 38% 60% 6% 0 19% 30% 38% 10%
ddI 100% 90% 0 0 0 0 0 10%
TDF 50% 10% 38% 30% 0 10% 13% 50%
ATV 19% 10% 13% 0 6% 0 63% 90%
IDV 56% 10% 6% 10% 6% 20% 31% 60%
LPV/r, liquid 69% 80% 13% 20% 0 0 19% 0
LPV/r, paediatric tablet 50% 10% 0 10% 19% 10% 31% 70%
LPV/r, adult tablet 81% 100% 0 0 13% 0 6% 0
LPV/r, adult capsule 31% 60% 19% 20% 6% 0 44% 20%
NFV 6% 20% 13% 0 0 20% 81% 60%
RTV, liquid 13% 50% 19% 20% 19% 0 50% 30%
RTV, capsule 38% 50% 13% 30% 0 0 50% 20%
SQV 13% 10% 13% 10% 25% 30% 50% 50%
*any formulation unless noted otherwise.
TA - TREAT Asia; SA - IeDEA Southern Africa; ABC - abacavir; ddI - didanosine; TDF - tenofovir; ATV - atazanavir; IDV - indinavir; LPV/r - ritonavir-boosted lopinavir;
NFV - nelfinavir; RTV - ritonavir; SQV - saquinavir.
Table 3 Paediatric antiretroviral therapy (ART) utilization among children on first-line ART at data transfer in TREAT
Asia and IeDEA Southern Africa
TREAT Asia (N = 1164) IeDEA Southern Africa (N = 4412)
Female, N (%) 608 (52) Female, N (%) 2179 (49)
Most common regimens, N (%) Most common regimens
AZT+3TC+NVP 529 (46) d4T+3TC+EFV 2154 (49)
AZT+3TC+EFV 299 (26) d4T+3TC+LPV/r 979 (22)
d4T+3TC+NVP 183 (16) d4T+3TC+NVP 671 (15)
d4T+3TC+EFV 53 (5) d4T+3TC+LPV/r+RTV 128 (3)
AZT+3TC+LPV/r 33 (3) AZT+3TC+NVP 119 (3)
Median age, months (IQR) at start 85 (47-119) Median age, months (IQR) at start 56 (22-96)
Median age, months (IQR) at data transfer 129 (90-163) Median age, months (IQR) at data transfer 79 (43-119)
Median months (IQR) on regimen 38 (20-58) Median months (IQR) on regimen 19 (9-31)
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adjustment for age, duration on ART, disease severity at
the time of failure and first-line regimen [13].
A wide range of second-line regimens was in use.
Unlike the United Nations data reporting that at least
46.7% of paediatric second-line regimens in the 59
LMICs it surveyed contained abacavir [1], this ARV was
infrequently used in either the TREAT Asia or the
IeDEA Southern Africa cohorts. Most of the second-line
regimens included recycling of a thymidine analogue
(i.e., zidovudine). It was unexpected that abacavir was
more difficult to access by clinical sites in Asia despite
being part of the WHO-recommended second-line regi-
men. The relatively higher cost of abacavir compared
with zidovudine may also be a deterrent to its use.
Access to a broader range of paediatric ARVs is needed
in order to maximize the potency of second- and third-
line regimens, whenever possible.
Another outcome of this survey was to document the
differences in use of stavudine between the regions.
Recent WHO recommendations for adult ART have
proposed setting up plans for phasing out stavudine by
2011 because of long-term toxicity with this drug [15].
Similar recommendations for children may also be justi-
fied [16]. Scaling up of paediatric treatment in many
developing countries depends on simple fixed-dose com-
binations and child-friendly adapted formulations, such
as dispersible tablets, improved palatability and heat-
stable formulations (for storage in tropical climates).
Examples include the need for ritonavir-boosted ataza-
navir and heat-stable ritonavir-boosted lopinavir in pala-
table paediatric formulations.
In addition, given the difficulties of accessing clean
water in many resource-limited rural settings, formula-
tions that require reconstitution should ideally be
avoided. Efforts are also needed to ensure that newer
drugs, such as raltegravir, darunavir and etravirine, are
also developed as heat-stable formulations and tested
for use in infants and young children as these represent
important potential options for both, and for improving
first-line regimens and as salvage therapy.
Finally, improving access to effective paediatric treat-
ment also requires improved access to diagnostic tools,
including PCR for early infant diagnosis and more wide-
spread access to viral load technologies for early diagnosis
of treatment failure. Although rarely available, the role of
resistance testing in LMIC settings continues to be
unclear. Further research on when and how HIV genotyp-
ing in heavily experienced children can be cost-effective is
needed to identify possible strategies for its use.
Our data are limited by their cross-sectional nature
and depth. The potential impact of changes in drug
access and national or global paediatric treatment guide-
lines are difficult to assess from our surveys and the
regional databases. Additional detail on the durability of
first-line regimens in the children with treatment failure
is available for the southern Africa cohort in a previous
publication [13], but has not yet been analyzed for the
Asian cohort. The survey on drug access did not sepa-
rate out drugs that could not be accessed from those
there were simply not used in the clinic.
The participating clinical centres are also largely urban
referral centres, preventing generalization of these results.
However, these cohorts include some of the most experi-
enced patients in these regions, who are facing challenges
today that are expected to arise for all children as they age
into adulthood. The lessons we are learning from these
children’s experiences with ART can be used to better pre-
pare national-level programmes for the future.
Conclusions
Although better use of first-line drugs can delay failure
and improve second-line outcomes, the need for second-
line paediatric ART in LMICs will continue to grow. The
Table 4 Paediatric antiretroviral therapy (ART) utilization among children on second-line ART at data transfer in
TREAT Asia and IeDEA Southern Africa
TREAT Asia (N = 137) IeDEA Southern Africa (N = 149)
Female, N (%) 69 (50) Female, N (%) 49 (33)
Most common regimens, N (%) Most common regimens
AZT+3TC+LPV/r 31 (23) AZT+ddI+LPV/r 54 (36)
AZT+ddI+LPV/r 29 (21) AZT+ddI+EFV 17 (11)
ddI+3TC+LPV/r 15 (11) AZT+TDF+LPV/r 14 (9)
LPV/r+IDV 8 (6) ABC+3TC+LPV/r 12 (8)
d4T+ddI+LPV/r 7 (5) d4T+3TC+LPV/r 8 (5)
Median age, months (IQR) at start 120 (78-145) Median age, months (IQR) at start 66 (29-112)
Median age, months (IQR) at data transfer 146 (102-173) Median age, months (IQR) at data transfer 104 (62-143)
Median months (IQR) on regimen 17 (9-38) Median months (IQR) on regimen 12 (4-18)
AZT - zidovudine; 3TC - lamivudine; NVP - nevirapine; d4T - stavudine; EFV - efavirenz; LPV/r - ritonavir-boosted lopinavir; ddI - didanosine; IDV - indinavir; ABC -
abacavir; TDF - tenofovir.
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second-line regimens must keep pace with children as
they transition to adolescence and adulthood. Ultimately,
t h e r ew i l lb el i m i t e db e n e f i tt o earlier diagnosis of treat-
ment failure unless providers and patients have access to
appropriate drugs for children to switch to.
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